alternatives to glp 1 injections of an ultra-long-acting investigational GLP-1 agonist led significant weight loss in people with overweight or obesity, with reductions continuing after a switch to once-monthly dosing, according to the ongoing VESPER REINVENTING MEDICINE - Blog /

In individuals with type 2 diabetes, another phase 2 clinical study demonstrated that after 12 weeks of efinopegdutide treatment, although no significant improvement in glycated hemoglobin (HbA1c) levels was observed, the effect on weight loss reached a high of 7.9%, well above the 0.7% weight reduction rate in the placebo group

and it provides antioxidant protection that reduces oxidative stress-induced hyperpigmentation

Understanding these factors helps clarify why prices vary and how to choose the right option

Oxidative stress increases with normal aging, and antioxidant support can support long-term wellness habits

& Tan, L

Ward before treatment